However, our experience suggests that in refractory anti‐MDA5 antibody‐positive CADM with rapidly progressive interstitial pneumonitis, tacrolimus trough‐concentration‐escalating dual therapy is a therapeutic strategy to be considered in the absence of a definitive and effective treatment regimen. The gene discussed is IFIH1; the disease is clinically amyopathic dermatomyositis.